BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026
BridgeBio Pharma, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $66.26
+4.7% in 3d after detection
Post-detection moves
1h
—
1d
+3.4%
3d
+4.7%
7d
+0.4%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS